Riviste scientifiche

Ancient natural nuclear reactors show how to store radioactive waste

New Scientist - Lu, 13/08/2018 - 22:00
Billions of years ago, uranium in the Earth’s crust underwent nuclear reactions on its own, and the remnants demonstrate a way to keep nuclear waste under control

We’ve identified the brain cells that let you control urination

New Scientist - Lu, 13/08/2018 - 18:00
We’ve all been there – desperately holding on for a toilet. Now the brain cells that help us do it have been identified, which may lead to new incontinence treatments

Asteroid strike may have forged the oldest rocks ever found on Earth

New Scientist - Lu, 13/08/2018 - 18:00
The oldest rocks ever found are over four billion years old and we don’t know how they formed – but a massive asteroid bombardment may be responsible

Orca who carried her dead infant is not alone – many animals grieve

New Scientist - Lu, 13/08/2018 - 16:49
A female orca has been seen carrying the body of her dead calf for 17 days, apparently grieving. Such displays of grief are remarkably common in nature

Rock layers show our sun has been in same cycle for 700 million years

New Scientist - Lu, 13/08/2018 - 14:29
Our star gets more and less active in a repeating cycle that lasts 11 years, and ancient rocks suggest it behaved the same way over 700 million years ago

NASA’s Parker Solar Probe is on its way to the sun, via Venus

New Scientist - Lu, 13/08/2018 - 14:15
After a false start on Saturday, NASA’s Parker Solar Probe blasted off on Sunday to begin a mission to enter the sun’s scorching atmosphere

Cybersecurity is failing us – and will continue to do so unless we act

New Scientist - Lu, 13/08/2018 - 12:00
Our current model of internet security is too vulnerable to the mistakes of individual programmers. Better alternatives exist – and should be deployed

Buzz: A beautiful book shows why modern bees are hippy wasps at heart

New Scientist - Lu, 13/08/2018 - 11:00
A beautifully illustrated new book details the evolutionary path that created modern bees from their ancient wasp ancestors - and why the apians’ future is uncertain

Tools reveal Easter Island may not have had a societal collapse

New Scientist - Lu, 13/08/2018 - 07:00
Tools used to make Easter Island’s famous statues have yielded a clue that suggests the Rapa Nui inhabitants that made them all got along with each other

Don’t miss: Taxidermied rabbits, mucky biology and the digital future

New Scientist - Sa, 11/08/2018 - 16:00
See a taxidermied rabbit in a silver goblet at show about human-animal hybrids, read about biology's muckier side, and listen to tough talk about our digital future

[Articles] Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial

The Lancet - Sa, 11/08/2018 - 00:30
PPF-treated LLINs provide greater protection against clinical malaria than do standard LLINs and could be used as an alternative to standard LLINs in areas with intense transmission of Plasmodium falciparum malaria and highly pyrethroid-resistant vectors.

[Comment] New opportunities for malaria vector control

The Lancet - Sa, 11/08/2018 - 00:30
Owing to the scale up of malaria control interventions, malaria morbidity and mortality have declined, with much of the decline attributed to the scale up of long-lasting insecticidal nets (LLINs).1 However, the 2017 World Malaria Report2 indicated that progress in reducing the burden of malaria has stalled and, in some countries, malaria cases and deaths are increasing. The causes of this stagnation are likely multifactorial and include stagnant donor investment, as well as the rise and spread of insecticide resistance.

[Editorial] Heart failure: the need for improved treatment and care

The Lancet - Sa, 11/08/2018 - 00:00
Great strides have been made in decreasing the prevalence of, and mortality from, ischaemic heart disease in the past decade or so. However, the prevalence of heart failure as the end result of many differing assaults on the heart is increasing worldwide. This increased prevalence is due to a mixture of population ageing and prolonged survival of patients with heart failure because of some treatment successes, and also due to the rising prevalence of risk factors, such as hypertension, diabetes, and obesity.

[Editorial] Introducing EU-wide surveillance of Lyme neuroborreliosis

The Lancet - Sa, 11/08/2018 - 00:00
On June 22, 2018, the European Commission issued an updated list of communicable diseases to be covered by epidemiological surveillance in the EU. This list now includes Lyme neuroborreliosis, the neurological manifestation of Lyme borreliosis, which is caused by tick-borne Borrelia burgdorferi sensu lato infection. The decision authorises the European Centre for Disease Prevention and Control (ECDC) to begin monitoring the EU-wide distribution of Lyme neuroborreliosis cases.

[Editorial] Khan faces tough test as Pakistan's new Prime Minister

The Lancet - Sa, 11/08/2018 - 00:00
Imran Khan is expected to take oath as Pakistan's new Prime Minister on Aug 14, after his Tehreek-e-Insaf party swept to victory with widespread support in the country's recent election. Khan inherits a nation riddled with corruption and facing a grave economic crisis, with loan defaults looming and a bailout from the International Monetary Fund looking inevitable. Coupled with the country's dismal performance on key health-related indicators, improving the state of health in Pakistan will be a difficult task.

[Comment] Age at type 1 diabetes onset: a new risk factor and call for focused treatment

The Lancet - Sa, 11/08/2018 - 00:00
Therapeutic options for diabetes have improved, allowing people with type 1 diabetes to live longer and healthier lives. However, life expectancy remains 8–13 years shorter and cardiovascular disease continues to be the leading cause of morbidity and mortality in type 1 diabetes.1,2 Attention has focused appropriately on modifiable cardiovascular disease risk factors such as glucose control, blood pressure, and cholesterol. However, non-modifiable cardiovascular disease risk factors, age at the time of the diagnosis being an example, might also help direct timing of therapy for modifiable risk factors.

[Comment] Salt and heart disease: a second round of “bad science”?

The Lancet - Sa, 11/08/2018 - 00:00
2 years ago, Andrew Mente and colleagues,1 after studying more than 130 000 people from 49 different countries, concluded that salt restriction reduced the risk of heart disease, stroke, or death only in patients who had high blood pressure, and that salt restriction could be harmful if salt intake became too low. The reaction of the scientific community was swift. “Disbelief” was voiced that “such bad science” should be published by The Lancet.2 The American Heart Association (AHA) refuted the findings of the study, stating that they were not valid,3 despite the AHA for many years endorsing products that contain markedly more salt than it recommends as being “heart healthy”.

[Comment] New regulations to cut valproate-exposed pregnancies

The Lancet - Sa, 11/08/2018 - 00:00
In 1948, as the UK's National Health Service (NHS) was born, “neurological” treatments consisted of antibiotics, B12 injections, and phenobarbital or phenytoin.1 Much has changed. In epilepsy alone, there are now about 26 anti-epileptic drugs (AEDs). Through much of this transformation, an AED has provided both hope and concern: valproate. Initially licensed for epilepsy in France in 1967,2 valproate is an effective AED recommended in England by the National Institute for Health and Care Excellence (NICE) as a first-line agent for generalised or unspecified epilepsy and second-line for focal epilepsy.

[World Report] Breast cancer in Venezuela: back to the 20th century

The Lancet - Sa, 11/08/2018 - 00:00
Facing scarcity of medicines and broken-down medical equipment, women diagnosed with breast cancer in Venezuela resort to more radical means of treatment. Hildegard Willer reports.

[World Report] Biosimilars for insulin: a cost-saving alternative?

The Lancet - Sa, 11/08/2018 - 00:00
The expiry of patents on an insulin analogue has opened the market to the production of biosimilar insulins, but it is unclear if this will ultimately benefit patients. Chris McCall reports
Condividi contenuti